It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chromobox protein homolog 2 (CBX2) exerts a multifaceted impact on the progression of aggressive cancers. The proteasome-dependent pathway is crucial for modulating CBX2 regulation, while the specific regulatory roles and mechanisms of deubiquitinating enzymes targeting CBX2 remain poorly understood. Mass spectrometry analysis identified ubiquitin-specific peptidase 27X (USP27X) as a deubiquitinating enzyme that targets CBX2. Overexpression of USP27X significantly enhances CBX2 levels by promoting deubiquitination, while deficiency of USP27X leads to CBX2 degradation, thereby inhibiting tumorigenesis. Furthermore, it has been revealed that glycogen synthase kinase 3 beta (GSK3β) can directly bind to and phosphorylate USP27X, thereby enhancing the interaction between USP27X and CBX2 and leading to further stabilization of the CBX2 protein. Clinically, the co-expression of high levels of USP27X and CBX2 in breast cancer tissues is indicative of a poor prognosis for patients with this disease. These findings collectively underscore the critical regulatory role played by USP27X in modulating CBX2, thereby establishing the GSK3β-USP27X-CBX2 axis as a pivotal driver of malignant progression in breast cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Inner Mongolia Medical University, College of Pharmacy, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392); Inner Mongolia Medical University, The Center for New Drug Safety Evaluation and Research, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392)
2 Inner Mongolia Medical University, Medical Innovation Center for Nationalities, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392)
3 Inner Mongolia Medical University, College of Traditional Chinese Medicine, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392)
4 Inner Mongolia Medical University, College of Pharmacy, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392)
5 Inner Mongolia Medical University, College of Mongolian Medicine, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392)
6 Inner Mongolia Medical University, Medical Experimental Center of Basic Medical School, Hohhot, China (GRID:grid.410612.0) (ISNI:0000 0004 0604 6392)